Anti-CLDN18.2 antibody, drug conjugate, and preparation method therefor and use thereof
AssigneeCspc Megalith Biopharmaceutical Co., Ltd.
InventorsXiwu Hui, Zhaopeng Sun, Weirong Cao, Bing Yao, Boning Liu, Xixin Hu, Can Yuan, Wenbin Li, Yancui Wang
Life of this patent
Estimating the term…
Abstract
The present application provides an anti-CLDN18.2 antibody and an antibody-drug conjugate prepared from the antibody. The antibody or the antibody-drug conjugate can effectively treat CLDN18.2 positive tumors, comprising but not limited to cancers represented by gastric cancer and pancreatic cancer.
Claims14
A conjugate, comprising an antibody or an antigen-binding fragment thereof conjugated with one or more drug molecules, wherein the antibody comprises a heavy chain and a light chain, and the heavy chain comprises three CDR regions having the amino acid sequences as set forth in SEQ ID NOs:
- 1, 2 and 3 respectively and the light chain comprises three CDR regions having the amino acid sequences as set forth in SEQ ID NOs:
- 4, 5 and 6 respectively, wherein the drug molecule is MMAE (Monomethyl auristatin E), the drug molecule is conjugated with the antibody or antigen-binding fragment thereof via a linker, which is linked to the antibody or antigen-binding fragment via an amino group, and the linker is NH2—(CH2—CH2—O)m—CH2—C(═O)—Val-Cit-p-aminobenzyloxycarbonyl (pABC), wherein m is an integer from 1 to 8, and the average drug antibody ratio is 2.
Dependencies are inferred from the claim text.